Purpose: To characterize prednisone use in pregnant women with rheumatoid arthritis using individual-level heat-maps and clustering individual trajectories of prednisone dose, and to evaluate the association between prednisone dose trajectory groups and gestational length.
| INTRODUCTION
Oral glucocorticoids are used to treat symptoms caused by several chronic diseases, including asthma, rheumatoid arthritis, and other autoimmune diseases. For pregnant women with these conditions, oral glucocorticoids may be used to manage flares or when other treatments regarded as riskier for chronic management are discontinued. [1] [2] [3] [4] Approximately 1% to 2% of pregnant women [5] [6] [7] and 20% to 40% of pregnant women with rheumatoid arthritis 8, 9 use oral glucocorticoids.
Despite frequent use of oral glucocorticoids during pregnancy among women with autoimmune diseases, the medications have been associated with a range of adverse perinatal outcomes in some studies including cleft lip with or without cleft palate, maternal infection, gestational diabetes, preeclampisa, preterm birth, and gestational age at delivery. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Several studies have reported that oral glucocorticoid use during pregnancy is associated with an approximately 2-fold or higher increased risk of preterm birth compared with women not using oral glucocorticoids. [16] [17] [18] [19] [20] [21] Notably, higher rheumatoid arthritis severity/ activity, which impacts prednisone use and dose, is also associated with an increased risk of preterm birth. 22 The literature contains limited information regarding the relation between oral glucocorticoid dose and gestational length. 23, 24 Oral glucocorticoid duration and dosage of use depend on a number of factors including disease severity, patient and physician preference, and whether the medication is being used to treat or prevent a flare. 1, 2 Defining medication exposure according to trimester of use removes exposure information, including dose changes, intensity of use, and coverage gaps, that is important for understanding how the medications are used during pregnancy and how these factors impact pregnancy outcomes.
To better understand oral glucocorticoid utilization patterns and exposure levels in women with rheumatoid arthritis during pregnancy, we aimed to characterize prednisone use according to daily and cumulative dose using individual plots and clustering individual trajectories. We also aimed to evaluate whether patterns of prednisone use were associated with gestational age at delivery. We were interested in the oral route of glucocorticoids because of their systemic effects.
Moreover, we focused on prednisone use in particular because it is the most commonly used oral glucocorticoid during pregnancy, 5, 7 and it accounted for 98% of all oral glucocorticoid use in the study population.
| METHODS

| Data source
This study used data collected by the MotherToBaby Autoimmune Diseases in Pregnancy Study, an ongoing prospective cohort study that aims to evaluate the effects of select medications and autoimmune diseases during pregnancy. 22, 25 Participants were from the United States and Canada and were self-referred, referred by their health care providers, or referred by MotherToBaby, a free counseling service of the Organization of Teratology Information Specialists that provides evidence-based information regarding medications and other exposures during pregnancy and lactation.
Trained study staff conducted semi-structured interviews with participants via telephone up to 4 times: at the time of study enrollment, at approximately 24 and 32 weeks' gestation, and after delivery.
Interviewers collected data from participants regarding demographics, socio-economic status (Hollingshead categories based on maternal and paternal education and occupation; possible range from highest = 1 to lowest = 5) 26 maternal health and behavior, names, dates, and dose of each medication used during pregnancy, and pregnancy outcomes.
Additionally, interviewers administered the Health Assessment Questionnaire Disability Index (HAQ; possible range from 0 = no disability to 3 = completely disabled), a validated self-assessment questionnaire to measure rheumatoid arthritis severity. 27, 28 Medical records were requested from all participants to help verify maternal report.
| Study population
Pregnant women with a last menstrual period between 2003 and 2014 were eligible for this study if they reported having rheumatoid arthritis and enrolled in the MotherToBaby Autoimmune Diseases in Pregnancy Study before gestational week 20 (Supplemental Figure 1 ).
Women were excluded who had a spontaneous or therapeutic abortion, were lost to follow-up or withdrew, or had incomplete pregnancy outcome information. Of the 526 women meeting the basic inclusion criteria, 55% reported using prednisone on at least 1 day during pregnancy. We excluded 239 (45%) women because they did not report any oral glucocorticoid use during pregnancy, 6
(1%) women because they used oral glucocorticoids other than prednisone, 6 (1%) women because they were missing all prednisone dose information, and 21 (4%) women who had another Autoimmune Diseases in Pregnancy Study-qualifying diagnosis, ie, ankylosing spondylitis, Crohn's disease, psoriasis, or psoriatic arthritis, because prednisone may have been used for these indications rather than rheumatoid arthritis. In total, there were 254 women included in the current study.
| Exposure information
The total number of days of prednisone use during pregnancy and prednisone daily dose and cumulative dose since the beginning of pregnancy were calculated for each woman on each gestational day using women's reported start and stop dates, frequency of use during start and stop dates, and doses. There were 6 women who were missing prednisone dose for some, but not all, of the days on which they reported using prednisone (see paragraph below). Median, minimum, and maximum total number of days of prednisone use, mean daily dose for days on which prednisone use was reported, and total cumulative dose during pregnancy were calculated.
KEY POINTS
• Prednisone timing of use, daily dose, and cumulative dose during pregnancy were variable across women with rheumatoid arthritis.
• Prednisone dose trajectory groups were associated with rheumatoid arthritis severity, non-biologic disease modifying anti-rheumatic drug use, and gestational age at delivery.
• Trajectory groups with the highest daily and cumulative doses of prednisone, compared with the lowest doses, were associated with shorter gestational age at delivery after adjusting for rheumatoid arthritis severity, disease modifying anti-rheumatic drug use, nonsteroidal anti-inflammatory drug use, and other factors.
• Given that the median cumulative dose of prednisone exposure during pregnancy was >1200 mg in this study, it is crucial to consider the impact of such doses on maternal and fetal outcomes.
| Individual plots
Prednisone daily dose and cumulative dose on each gestational day were plotted using a heat-map graphic for each individual, with gestational day as the x-axis. The plot legends were capped at ≥50 mg of prednisone per day and ≥2000 mg of cumulative prednisone dose. The 6 women with incomplete prednisone dose information were identified with asterisks on the individual plots.
| Trajectory groups
We grouped women in K clusters of similar individual trajectories of prednisone dose using k-means clustering in R statistical software 29 (with default settings) on our longitudinal dataset that contained dose per gestational day. This approach classifies each woman into the cluster in which the Euclidean distance between her dose on each day and the cluster mean dose on each day is minimized. This approach requires that women have the same number of follow-up days. To avoid including postpartum days for women with shorter gestational lengths, a uniform window of observation that ended before delivery was needed. Therefore, the k-means clustering analysis was restricted to women who did not deliver before 32 gestational weeks and was limited to prednisone use during the first 32 gestational weeks. The algorithm was considered for K = 2 to K = 10. To select the number K of clusters for the daily dose analysis, we required the cluster to have no fewer than 5% of the total number of women and required the trajectories to be clinically meaningful. Setting K = 4 satisfied these criteria. We also set K = 4 for the cumulative dose analysis for consistency between the daily dose and cumulative dose clustering analyses. We plotted the observed daily mean and 95% confidence intervals (CIs) for each cluster, ie, trajectory group, on each gestational day. Then, we plotted the dose on each gestational day for the first 32 gestational weeks using heat maps for each individual stratified by trajectory group. For each trajectory group, we calculated the mean of members' mean daily dose of prednisone on days of use and the mean total cumulative dose of prednisone during the first 32 gestational weeks.
We evaluated the associations between the trajectory groups and e Average daily dose was calculated for days on which prednisone was used. models, the reference groups were those with lowest daily and cumulative doses, and 3 women with missing covariate values were excluded.
3 | RESULTS
| Cohort characteristics
The mean gestational age at enrollment was 11.1 weeks (standard deviation: 4.5 weeks), and the mean maternal age was 32.4 years (standard deviation: 4.6 years) ( Table 1) . Most women were non-Hispanic White (76.8%) and had the highest 2 levels of socio-economic status (78.0%).
At the time of enrollment, the mean HAQ score was 0.7. Moreover, use of nb-DMARDs, b-DMARDs, and NSAIDs was common.
| Total cumulative days of use, daily dose, and total cumulative dose of prednisone
Women used prednisone on 3 to 292 days during pregnancy (Table 1) , with a median total of 199.5 days. The range of prednisone daily doses varied widely with some women taking less than 1 mg and others taking up to 60 mg, and the median daily dose was 7 mg. Total cumulative dose during pregnancy ranged from 8 to 6225 mg, and the median total cumulative dose was 1234 mg. 
| Individual plots
Prednisone timing of use, daily dose, and cumulative dose during pregnancy were variable across individuals (Figures 1, 2) . After initiating prednisone use during pregnancy, total cumulative dose tended to accumulate gradually for most women.
| Trajectory groups
There were 248 women who delivered at or after 32 gestational weeks and were eligible for k-means clustering. The trajectory group means for members' mean daily dose of prednisone and mean total cumulative dose of prednisone during the first 32 gestational weeks are reported in Table 2 . With 4 daily dose trajectory groups ( Figure 3 and Supplemental Abbreviations: HAQ, Health Assessment Questionnaire; SD, standard deviation.
Daily dose: ANOVA P < 0.01 for gestational age at delivery, HAQ at enrollment, and non-biologic disease modifying antirheumatic drugs.
Cumulative dose: ANOVA P < 0.01 for gestational age at delivery and HAQ at enrollment, ANOVA P = 0.01 for non-biologic disease modifying antirheumatic drugs.
a Average daily dose was calculated for days on which prednisone was used.
b Missing for 1 woman.
c Use during pregnancy before gestational week 32. Most individuals fell in the same group based on both daily and cumulative dose, such that 92% of daily dose group 1 was in cumulative dose group 1, 72% of daily dose group 2 was in cumulative dose group 2, 83% of daily dose group 3 was in cumulative dose group 3, and 93% of daily dose group 4 was in cumulative dose group 4.
Daily dose and cumulative dose trajectory groups were not associated with gestational age at enrollment, maternal age, race/ethnicity, socio-economic status, pre-pregnancy overweight/obesity, biologic DMARDs, or NSAIDs. HAQ scores varied across trajectory groups (P-values <0.01) as did the frequency of nb-DMARD use before gestational week 32 (P < 0.01 for daily dose trajectories and P = 0.01 for cumulative dose trajectories), which was lowest in Group 1 for daily and cumulative dose trajectories. Furthermore, gestational age at delivery varied across trajectory groups (P-values <0.01); for daily dose trajectory groups, the mean gestational age at delivery was 35.7 weeks for group 1, 37.6 weeks for group 2, 38.5 weeks for group 3, and 38.8 weeks for group 4 ( Table 2 ). After adjusting for HAQ score at enrollment, nb-DMARD use, and other covariates, the highest 2 daily dose trajectory groups were associated with shorter gestational age at delivery compared with the lowest daily dose trajectory group (Table 3 
| DISCUSSION
In this study of prospectively followed pregnancies in women with rheumatoid arthritis, 55% reported using prednisone. The individuallevel plots in this study illustrate variability in prednisone dose, length of courses, and timing of courses during pregnancy. Previous studies have used clustered trajectories to summarize complex individual-level medication utilization trajectories, but only 2 such studies summarized medication use during pregnancy.
30-33
Hurault-Delarue et al used k-means methodology to identify trajectories of psychotropic medications dispensed during pregnancy. 32 Moreover, the authors linked trajectories of high exposure to anxiolytics or hypnotics with an adverse neonatal outcome compared with no exposure. 33 Although trajectory groups provide more information regarding medication utilization than binary trimester categorization of medication use, each trajectory group contains heterogeneity. Within-group heterogeneity was especially apparent for the prednisone daily dose trajectory groups (compared with cumulative dose trajectory groups) in this study, eg, daily dose group means were always non-zero although individuals had gaps in prednisone use.
This study has some limitations to consider. First, because changes in dose are tied to disease severity, residual confounding by disease severity is a concern. Although we adjusted for disease severity at enrollment, as well as the use of other rheumatoid arthritis-related medications, the association between the highest dose trajectory groups and shorter gestational length could reflect residual confounding by changes in disease severity later in pregnancy. Second, some of the trajectory groups contained few women, which could result in chance findings. This is especially a concern for the highest cumulative and daily dose trajectories, which included only 11 or 12 women.
Third, errors in a woman's reported dates of prednisone use and dose could result in misclassification into a trajectory group other than the one that would best fit her actual trajectory of use. Furthermore, reporting errors across women in the cohort could change the shape of the trajectories from what they would have been without errors. Any measurement error would be expected to attenuate associations between the trajectory groups and gestational age at delivery, assuming that the errors were independent of the outcome. To minimize measurement error in this study, maternal report of prednisone use was obtained primarily during pregnancy as opposed to months after delivery. Finally, generalizability is a concern for this study because women were primarily non-Hispanic White, had relatively high socioeconomic status, and older maternal age. The trajectory patterns may not generalize to other populations if prednisone use during pregnancy varies by such demographic factors.
In head-to-head comparison of prednisone dose profiles in women with rheumatoid arthritis, the highest prednisone daily dose and cumulative dose trajectories compared with the lowest dose trajectories were associated with shorter gestational age at delivery after adjusting for disease severity at enrollment, DMARDs, NSAIDs, and other factors. As increasing dose is expected to be associated with increasing disease severity, results may reflect residual confounding by disease severity late in pregnancy. Given that the median cumulative dose of prednisone exposure during pregnancy exceeded 1200 mg for women with rheumatoid arthritis in this study, it is crucial to consider the impact of such doses on maternal and fetal outcomes in future studies, while accounting for disease severity.
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